Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 1436 • 2016 ACR/ARHP Annual Meeting
TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis
Hiroaki Hayashi, Takafumi Harada, Shunsuke Demizu, Fumito Tatsuzawa, Ken Sato, Morihiro Mitsuya, Kenji Tanaka, Kazuhiko Yonekura, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: The family of Janus kinases (JAKs) plays important roles in signaling pathway mediated by various cytokine receptors. An aberrant activation of JAK-STAT signaling…
Abstract Number: 1438 • 2016 ACR/ARHP Annual Meeting
Tofacitinib Restores Reverse Cholesterol Transport Inhibition Induced By Inflammation. Understanding the Lipid Paradox
Sandra Pérez-Baos¹, Juan I. Barrasa², Paula Gratal¹, Ane Larrañaga-Vera¹, Iván Prieto-Potin¹, Gabriel Herrero-Beaumont¹ and Raquel Largo¹, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ²Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain
Background/Purpose: Patients with active rheumatoid arthritis (RA) have significantly increased cardiovascular (CV) morbidity and mortality, paradoxically in association with reduced circulating levels of total cholesterol…
Abstract Number: 1454 • 2016 ACR/ARHP Annual Meeting
Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis
Julie Di Paolo¹, David Alonzo², Christian Franci³, Terry Gentzler¹, Li Li⁴, Bernard Murray⁵ and Jim Zheng⁵, ¹Biology, Gilead Sciences, Foster City, CA, ²FPD, Gilead Sciences, Foster City, CA, ³Biology, Gilead Sciences, Foster, CA, ⁴Gilead Sciences, South San Francisco, CA, ⁵DMPK, Gilead Sciences, Foster City, CA
Background/Purpose: Here we demonstrate that 1) the single agent activity of GS-9876 is efficacious in a late stage rat model of collagen-induced arthritis (CIA);…
Abstract Number: 1586 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials
Alvin F. Wells¹, Maria Greenwald², John D. Bradley³, Jahangir Alam³, Vipin K. Arora³ and Cynthia E. Kartman³, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²Desert Medical Advances, Palm Desert, CA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari), an oral selective JAK1 and JAK2 inhibitor, has been shown to be safe and efficacious compared to placebo (PBO) in two Phase…
Abstract Number: 1629 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics of ABT-494 with the Once-Daily Extended-Release Tablet Formulation Being Utilized in the Ongoing Rheumatoid Arthritis Phase 3 Trials
Mohamed-Eslam Mohamed¹, Jiewei Zeng², In-Ho Song³ and Ahmed A. Othman³, ¹Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ²AbbVie, North Chicago, IL, ³AbbVie Inc., North Chicago, IL
Background/Purpose: ABT-494 is a selective Janus Kinase 1 inhibitor. In two Phase 2b studies in subjects with rheumatoid arthritis, 6 mg and 12 mg twice-daily…
Abstract Number: 1678 • 2016 ACR/ARHP Annual Meeting
JAK STAT Kinase Cascade Regulates the IL-23/IL-17 Cytokine Axis in Psoriatic Arthritis
Siba P. Raychaudhuri¹ and Smriti K. Raychaudhuri², ¹Davis, CA, ²Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA
Background/Purpose: Aberrant activation of IL-23/IL-17 cytokine axis is a dominant pathology in the psoriatic disease. IL-23 regulates expansion/maintenance/functional maturation of Th17 cells. Th17 cells along…
Abstract Number: 1905 • 2016 ACR/ARHP Annual Meeting
Therapeutic Targeting of JAK/STAT Pathway Inhibits Follicular Helper T Cell Maturation and Function
Flora Sagez and Jacques-Eric Gottenberg, Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: T follicular helper (Tfh) cells represent a CD4+T cell subset specialized to provide help to B cells and to induce memory B cell and…
Abstract Number: 2555 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis
Katerina Chatzidionysiou¹, Sharzad Emamikia², Jackie L. Nam³, Sofia Ramiro⁴, Josef Smolen⁵, Désirée van der Heijde⁶, Maxime Dougados⁷, Johannes WJ Bijlsma⁸, Gerd Burmester⁹, Marieke Scholte-Voshaar¹⁰, Ronald van Vollenhoven^11,12 and Robert Landewé¹³, ¹Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Paris Descartes University, Paris, France, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁹Charité University Hospital, Berlin, Germany, ¹⁰EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ¹¹Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ¹³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: To inform the task force for the 2016 update of the EULAR recommendations for the management of RA on the evidence regarding the efficacy…
Abstract Number: 2563 • 2016 ACR/ARHP Annual Meeting
Hypoxia Induce Slug Expression Via JAK/STAT3 Pathway in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Hyungjin Kim¹, Hyemin Jeong², Jaejoon Lee², Hoon-Suk Cha¹, Eun-Mi Koh³, Eun-Jung Park⁴ and Young Hee Eun¹, ¹Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Medicine, Division of Rheumatology, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Jeju, South Korea
Background/Purpose: Accumulating evidence implicates hypoxia in the pathogenesis of rheumatoid arthritis (RA). The effect of hypoxia on the expression of Slug, a transcriptional repressor that…
Abstract Number: 2616 • 2016 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients
Peter C. Taylor¹, R Westhovens², Luc Meuleners³, Birgen Meuleman⁴, Yang Pan⁵, Veerle Vyncke³, Annegret Van der Aa³, Pille Harrison³, Chantal Tasset³ and René Galien⁶, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³Galapagos NV, Mechelen, Belgium, ⁴2Bridge, Turnhout, Belgium, ⁵Gilead Sciences, Foster City, CA, ⁶102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France
Methods : Patients with active RA on stable dose of MTX were randomized 1:1:1:1:1:1:1 in a double blind manner to receive either placebo (PBO) or…
Abstract Number: 2786 • 2016 ACR/ARHP Annual Meeting
The Janus Kinase Inhibitor Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
Yasuko Furumoto¹, Carolyne K. Smith², Luz P. Blanco³, Wanxia L. Tsai⁴, Wenpu Zhao⁵, Victoria Hoffmann⁶, Seth Thacker⁷, Giuseppe Sciumè⁸, Leti Nuñez¹, Alan Remaley⁹, John J O'Shea¹⁰, Mariana Kaplan¹¹ and Massimo G. Gadina¹², ¹NIAMS NIH, Translational Immunology Section, Office of Science and Technology, Bethesda, MD, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵NIAMS NIH, Systemic Autoimmunity Branch, Bethesda, MD, ⁶Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, ⁷NHLBI NIH, Lipoprotein Metabolism Section, Bethesda, MD, ⁸NIAMS NIH, Molecular Immunology and Inflammation Branch, Bethesda, MD, ⁹NHLBI, National Institutes of Health, Bethesda, MD, ¹⁰NIAMS NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ¹¹NIAMS/NIH, Bethesda, MD, ¹²Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Dysregulation of innate and adaptive immune responses contributes to the pathogenesis of systemic lupus erythematosus (SLE) and its associated premature vascular damage. To date,…
Abstract Number: 3025 • 2016 ACR/ARHP Annual Meeting
The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies
Mark C. Genovese¹, R Westhovens², Arthur Kavanaugh³, Luc Meuleners⁴, Annegret Van der Aa⁴, Pille Harrison⁴ and Chantal Tasset⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³University of California San Diego, La Jolla, CA, ⁴Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that showed rapid and sustained improvements of signs and symptoms of active rheumatoid…
Abstract Number: 3034 • 2016 ACR/ARHP Annual Meeting
A Selective JAK1 Inhibitor, Filgotinib Suppresses Lymphocytic Infiltration in Salivary Gland of Non Obese Diabetic Mice Via Suppression of BAFF and Chemokine Production of Salivary Gland Epithelial Cells
Jennifer Lee¹, Seo Hwa Kim², Haneul Kim³, Seung-Ki Kwok⁴, Ji Hyeon Ju⁵ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Interferon(IFN) signatures are upregulated in patients with primary Sjogren’s syndrome (pSS) and interferons are considered to play a pathogenic role in pSS. Therefore, Janus…
Abstract Number: 3208 • 2016 ACR/ARHP Annual Meeting
Preliminary Response to JAK1/2 Inhibition with Baricitinib in “Candle”,“Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN Mediated Autoinflammatory Diseases
Gina A. Montealegre Sanchez¹, Adam Reinhardt², Paul Brogan³, Dawn C. Chapelle⁴, Hanna Kim⁴, Samantha Judd⁴, Bahar Kost⁴, Michelle O'Brien⁴, Wendy Goodspeed⁵, Robert A. Colbert⁴, Meryl Waldman⁶, Deborah L. Stone⁷, Ling Gao⁸, JA Dare⁸, Susanne Schalm⁹, Thomas L. Klausmeier¹⁰, Sara Murias¹¹, Yackov Berkun¹², Diane Brown¹³, John D. Carter¹⁴, Fehime K Eroglu¹⁵, A. Zlotogorski¹⁶, Philip Hashkes¹⁷, Helmut Wittkowski¹⁸, Suzanne Ramsey¹⁹, Seza Ozen²⁰, Adriana Almeida de Jesus²¹ and Raphaela Goldbach-Mansky²², ¹NIAID/NIH, Bethesda, MD, ²Rheumatology, Children's Hosp of Omaha/UNMC, Omaha, NE, ³UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁴NIAMS/NIH, Bethesda, MD, ⁵Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁶NIDDK/NIH, Bethesda, MD, ⁷NHGRI/NIH, Bethesda, MD, ⁸University of Arkansas for Medical Sciences, Little Rock, AR, ⁹LMU Munich, Munich, Germany, ¹⁰Riley Hospital for Children, Indianapolis, IN, ¹¹Hospital Infantil La Paz, Madrid, Spain, ¹²Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ¹³Children's Hospital Los Angeles, Los Angeles, CA, ¹⁴Division of Rheumatology, University of South Florida, Tampa, FL, ¹⁵Department of Pediatrics, Hacettepe University Hospitals, Ankara, Turkey, ¹⁶Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ¹⁷Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ¹⁸Pediatrics, University of Muenster, Muenster, Germany, ¹⁹Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ²⁰Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²²Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Chronically elevated serum IP-10 (CXCL10) levels, and a prominent “interferon (IFN)-response gene signature” in patients with chronic neutrophilic dermatosis with lipodystrophy and elevated temperatures…
Abstract Number: 484 • 2016 ACR/ARHP Annual Meeting
Targeting the BTK-JAK Axis in Preclinical Models of Rat Collagen-Induced Arthritis with GS-4059 in Combination with a JAK Inhibitor
Julie Di Paolo¹, Christian Franci², Terry Gentzler¹, Bernard Murray³ and Li Li⁴, ¹Biology, Gilead Sciences, Foster City, CA, ²Biology, Gilead Sciences, Foster, CA, ³DMPK, Gilead Sciences, Foster City, CA, ⁴Gilead Sciences, South San Francisco, CA
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) mediates signaling in hematopoietic cells important for the initiation and progression of rheumatoid arthritis (RA). GS-4059 is an oral,…

« Previous Page
1
…
5
6
7
8
9
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].